P2Y12 receptor inhibitor therapy for secondary prevention of patients with stable coronary artery disease. P2Y12 receptor inhibitor therapy for secondary.

Slides:

Advertisements

Similar presentations

Bangalore S, et al. β-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. JAMA. 2012;308(13): ?

Advertisements

Date of download: 5/29/2016 Copyright © The American College of Cardiology. All rights reserved. From: AACVPR/ACC/AHA 2007 Performance Measures on Cardiac.

Date of download: 7/8/2016 Copyright © The American College of Cardiology. All rights reserved. From: Fractional Flow Reserve Versus Angiography for Guiding.

Date of download: 9/19/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Association of Public Reporting for Percutaneous.

Subgroup analyses for mortality after treatment with coronary artery bypass graft (CABG) or percutaneous coronary intervention (PCI). LAD, left anterior.

Algorithm for preoperative management of patients taking antiplatelet therapy. ACS, acute coronary syndrome; BMS, bare metal stent; DES, drug-eluting stent;

NORSTENT Trial design: Patients with obstructive coronary artery disease were randomized to a drug-eluting stent (DES) (n = 4,504) versus a bare-metal.

Robert A. Guyton, MD The Annals of Thoracic Surgery

Copyright © 2013 American Medical Association. All rights reserved.

Figure 3 One-year adverse events (death, post-discharge myocardial infarction, revascularization) after PCI according to patients who (A) would not have.

Comparison of Bare-Metal Stents and Drug-Eluting Stents in Coronary Ostial Lesions (from the National Heart, Lung, and Blood Institute Dynamic Registry)

Ischaemic Heart Disease Acute Coronary Syndrome

Glenn N. Levine et al. JACC 2016;68:

Achieving Long-Term Protection Post-MI

The Use of Antiplatelet Therapy in the Outpatient Setting: Canadian Cardiovascular Society Guidelines Alan D. Bell, MD, CCFP, André Roussin, MD, FRCPC,

Glenn N. Levine et al. JACC 2016;68:

Manuel Caceres, MD, Darryl S. Weiman, MD, JD

Robert A. Guyton, MD The Annals of Thoracic Surgery

New antiplatelet drugs and new oral anticoagulants

Death, target vessel revascularisation (TVR) and myocardial infarction (MI) with bioresorbable vascular scaffold (BVS) versus drug-eluting stent (DES)

Nat. Rev. Cardiol. doi: /nrcardio

2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease Glenn N. Levine, MD, FACC, FAHA,

Perioperative management of antiplatelet therapy

P. Foëx British Journal of Anaesthesia

BASKET-PROVE II Trial design: Subjects with stable or unstable coronary artery disease undergoing stent implantation were randomized to a biodegradable-polymer.

Peter K. Smith, MD The Journal of Thoracic and Cardiovascular Surgery

Peter K. Smith, MD The Annals of Thoracic Surgery

J. Trevor Posenau, MD, Daniel M. Wojdyla, MS, Linda K

Perioperative antiplatelet therapy: the case for continuing therapy in patients at risk of myocardial infarction P.-G. Chassot, A. Delabays, D.R. Spahn

NIPPON Trial design: Patients undergoing percutaneous coronary intervention were randomized to short-term dual antiplatelet therapy (DAPT) (6 months; n.

Effect of PCI on 1-year risk of all-cause mortality and major cardiovascular outcomes. CABG, coronary artery bypass grafting; CI, confidence interval (bars);

Why surgery won the SYNTAX trial and why it matters

Coronary revascularisation rate (total 5

Any and definite stent thrombosis (ST) and in-device late lumen loss (LLL) with bioresorbable vascular scaffold (BVS) versus drug-eluting stent (DES) in.

Tornado diagram of one-way deterministic sensitivity analysis.

Kaplan-Meier curves: revascularisation rate (PCI or CABG) was significantly higher (p

John A. Bittl et al. JACC 2016;68:

Hisato Takagi, MD, PhD, Hideaki Manabe, MD, Takuya Umemoto, MD, PhD

Kaplan-Meier estimate of mortality in 1798 propensity score matched pairs with a propensity score >0.5 for the whole observational period. Kaplan-Meier.

(A) Safety outcome: risk of major bleeding between triple antiplatelet therapy (TAPT) versus dual antiplatelet therapy (DAPT). (A) Safety outcome: risk.

(A) Meta-analysis of repeat revascularisation in randomised trials.

Death, target vessel revascularisation (TVR) and myocardial infarction (MI) with bioresorbable vascular scaffold (BVS) versus drug-eluting stent (DES)

Current Clinical Outcomes of Percutaneous Coronary Intervention and Coronary Artery Bypass Grafting Michael J. Mack, MD, Syma L. Prince, RN, Morley Herbert,

Markov model scheme. Markov model scheme. Patients start (state 0) with uncomplicated PCI revascularisation; then cycle between health states until death.

(A) Primary cardiovascular outcome: risk of major adverse cardiovascular effects (MACE) between triple antiplatelet therapy (TAPT) versus dual antiplatelet.

Characteristics of included studies

(A) Multivariable Cox regressions showing the association of higher CHA2DS2-Vasc scores (≥6) and (B) R2CHA2DS2-Vasc scores (≥7) with 1-year mortality (CABG,

Cox regression of proportion mortality in the first 8 years for patients with three-vessel disease with a significant difference between the treatment.

Change in 6 min walk distance from baseline to each follow-up time for subjects randomised to CABG and to medical therapy alone. The median change and.

Glenn N. Levine et al. JACC 2011;58:e44-e122

Kaplan–Meyer survival curve of 1313 patients following primary PCI

Correlation of calibrated integrated backscatter (cIB) with log10 total fibrosis (A) and log10 interstitial fibrosis (B) in patients undergoing coronary.

Figures showing the effects of a potential 30% relative reduction in events with next-generation drug-eluting stents in the percutaneous coronary intervention.

Antithrombotic strategies in patients on long-term oral anticoagulation therapy undergoing percutaneous coronary intervention. ACS: acute coronary syndrome;

Leslee J. Shaw et al. JIMG 2010;3:

(A) Primary platelet reactivity outcome: difference in platelet reactivity units (PRU) after treatment between triple antiplatelet therapy (TAPT) versus.

A model of variation and accelerating factors in the process of acute care chain of patients with STEMI going for primary PCI. PCI, percutaneous coronary.

Ticagrelor versus prasugrel; risk ratio with 95% CIs for the primary composite end point, primary composite end point in those undergoing PCI, myocardial.

Summary of STICH trial patients included in the analysis of 6 min walk distance. Reasons for non-inclusion at each follow-up time are given. CABG, coronary.

Effect of PCI on 3 to 5-year risk of all-cause mortality and major cardiovascular outcomes. CABG, coronary artery bypass grafting; CI, confidence interval.

Improved Long-Term Survival for Diabetic Patients With Surgical Versus Interventional Revascularization Paul Kurlansky, MD, Morley Herbert, PhD, Syma.

Percentage of percutaneous coronary interventions using drug-eluting stents in a National Health Service setting in England—National Institute for Health.

Result of coronary angiogram among patients with and without diabetes admitted with first-time acute coronary syndrome (a significant stenosis was defined.

Kaplan-Meier estimate of mortality in the two treatment strategies with significant difference between the two groups (log-rank test

Propensity score-matching

The Clinical Significance and Management Implications of Chronic Total Occlusion Associated With Surgical Coronary Artery Revascularization Lorenzo Azzalini,

Forest plot illustrating the risk ratio of myocardial infarction

FFR guided deferral of PCI in patients with ACS and stable coronary artery disease (SCAD). FFR guided deferral of PCI in patients with ACS and stable coronary.

Proposed future revascularisation strategy in patients with ESRD based on our current results and previous guideline recommendations. Proposed future revascularisation.

Adjusted. ORs for outcomes by maintenance P2Y12 treatment

Presentation transcript:

P2Y12 receptor inhibitor therapy for secondary prevention of patients with stable coronary artery disease. P2Y12 receptor inhibitor therapy for secondary prevention of patients with stable coronary artery disease. BMS, bare metal stent; CABG, coronary artery bypass graft surgery; CV, cardiovascular; DAPT, dual antiplatelet therapy; DES, drug-eluting stent; MI, myocardial infarction; PCI, percutaneous coronary intervention. Sophie Degrauwe et al. Open Heart 2017;4:e000651 ©2017 by British Cardiovascular Society